MARKET OUTLOOK · Q2 2026

Nifty 50: rangebound with bullish tilt

Support at 24,200; resistance 25,100. Banking and IT likely to lead. FII buying improved in last fortnight.

🔼 4.2% expected upside
SECTOR WATCH

Pharma & Defence in focus

Government Capex push and USFDA approvals buoy Pharma. Defence order book at record high.

⚡ momentum strong
ECONOMIC INDICATOR

CPI inflation cools to 4.7%

Lower crude and food prices boost sentiment. RBI likely to hold rates, but commentary dovish.

📉 inflation under control

Tailored investment solutions

Strategies designed for different horizons — all backed by rigorous research.

Multibagger Stocks

target 100%+ · under 4 months

High‑conviction ideas from small & midcap space. Fundamental bottom‑up research with growth catalysts.

Weekly Jackpot

10–15% weekly · short term

Momentum picks with high probability setup. Strict stop loss and risk‑reward of minimum 1:3.

Sure Shot Intraday

daily calls · high accuracy

Level‑based trading calls with live entry, target & stoploss. Derived from option chain and OI analysis.

⚡ Indian equity market overview
📈 Nifty Midcap 150 +14% YTD 💼 FII net buyers ₹26,000 Cr in May 🏭 Q4 earnings beat in 62% of Nifty cos
12.3%
Nifty 1Y return
19.8%
Midcap 1Y return
26
stocks with 'buy' rec.

Our research model combines quarterly earnings revision, FII/DII activity, and technical breakout confirmation.


⏤ research discipline · transparency · consistent returns ⏤